These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 33170434)
1. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis. Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434 [TBL] [Abstract][Full Text] [Related]
2. Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome. Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ Curr Med Res Opin; 2021 Mar; 37(3):431-441. PubMed ID: 33411573 [TBL] [Abstract][Full Text] [Related]
3. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Front Neurol; 2020; 11():598496. PubMed ID: 33414758 [No Abstract] [Full Text] [Related]
4. Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population. Nazareth T; Datar M; Yu TC Neurol Ther; 2019 Dec; 8(2):383-395. PubMed ID: 31564036 [TBL] [Abstract][Full Text] [Related]
5. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120 [TBL] [Abstract][Full Text] [Related]
6. Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis. Hayes K; Panaccio MP; Goel N; Fahim M Rheumatol Ther; 2021 Mar; 8(1):327-346. PubMed ID: 33400194 [TBL] [Abstract][Full Text] [Related]
7. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047 [TBL] [Abstract][Full Text] [Related]
8. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications. Philbin M; Niewoehner J; Wan GJ Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis. Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568 [TBL] [Abstract][Full Text] [Related]
10. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839 [TBL] [Abstract][Full Text] [Related]
11. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Gold LS; Nazareth TA; Yu TC; Fry KR; Mahler NH; Rava A; Waltrip Ii RW; Hansen RN Pediatric Health Med Ther; 2019; 10():195-207. PubMed ID: 32099512 [TBL] [Abstract][Full Text] [Related]
12. Cost per response analysis of repository corticotropin injection Wan GJ; Chopra I; Niewoehner J; Hunter SF Drugs Context; 2020; 9():. PubMed ID: 33408750 [TBL] [Abstract][Full Text] [Related]
13. A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy. Leist TP; Cole M; Verma S; Keenan A; Le HH Mult Scler Relat Disord; 2023 Oct; 78():104917. PubMed ID: 37597349 [TBL] [Abstract][Full Text] [Related]
14. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence. Wan GJ; Niewoehner J; Hayes K Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803 [TBL] [Abstract][Full Text] [Related]
15. A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States. Nelson WW; Philbin MJ; Gallagher JR; Heap K; Carroll S; Wan GJ Rheumatol Ther; 2017 Dec; 4(2):465-474. PubMed ID: 29071588 [TBL] [Abstract][Full Text] [Related]
16. Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis. Hayes K; Niewoehner J; Rice JB; Downes N; Hagopian E; Ma I; Wan GJ Adv Ther; 2023 Nov; 40(11):4999-5015. PubMed ID: 37728695 [TBL] [Abstract][Full Text] [Related]
17. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis. Mirsaeidi M; Baughman RP; Sahoo D; Tarau E Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607 [TBL] [Abstract][Full Text] [Related]
18. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®). Gold LS; Suh K; Schepman PB; Damal K; Hansen RN Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977 [TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection. Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332 [TBL] [Abstract][Full Text] [Related]